Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ALT Altimmune, Inc. Common Stock
$4.58 -0.77% -0.04
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ALT stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 568.6M
Enterprise value 287.8M
Trailing PE -3.3880596730246
Forward PE -3.7167559
PEG Ratio 0.098561735942535
Enterprise to EBITDA -3.186
Enterprise to revenue 14391.291
Price to book MRQ 2.3853683
Price to sales TTM 28991.098

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 20000
EBITDA -90343000
Diluted EPS TTM -1.06
Total Cash (MRQ) 210.8M
Current ratio (MRQ) 17.183
Operating Cash Flow (TTM) -66352000

ALT trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months
Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.